Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02149940
NCT02149940
Completed
N/A

Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.

Universitaire Ziekenhuizen KU Leuven1 site in 1 country29 target enrollmentApril 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHeart Failure

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
29
Locations
1
Primary Endpoint
the number of heart-failure related pharmaceutical interventions
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted.

In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
October 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •75 years or older
  • •diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure'
  • •diagnosis had to be confirmed by a recent echocardiogram

Exclusion Criteria

  • •not Dutch speaking
  • •treatment restrictions had been applied on admission

Outcomes

Primary Outcomes

the number of heart-failure related pharmaceutical interventions

Time Frame: during hospital stay (average of 14 days)

Secondary Outcomes

  • acceptance rate of the pharmaceutical interventions(during hospital stay (average of 14 days))
  • clinical feasibility of the accepted interventions(during hospital stay (average of 14 days))

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 4
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection Fraction
NCT03948685Yonsei University300
Terminated
Phase 4
BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)Congestive Heart Failure
NCT00433043St. Luke's-Roosevelt Hospital Center2
Completed
Phase 1
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney FunctionCongestive Heart FailureRenal Impairment
NCT05599997Bayer32
Unknown
N/A
Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart FailureChronic Heart Failure
NCT02282618Harbin Medical University180
Completed
Phase 1
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy ParticipantsHeart Failure
NCT04722562Bayer27